Flavivirus DNA vaccines - Good science, uncertain future

Journal of Infectious Diseases

Volumn 196, Issue 12, 2007, Pages 1721-1723

  Petersen, Lyle R ^a   Roehrig, John T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; WEST NILE VACCINE; YELLOW FEVER VACCINE; DNA VACCINE; VIRUS VACCINE;

CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HEMORRHAGIC FEVER; HUMAN; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; SHOCK; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS ENCEPHALITIS; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; FLAVIVIRUS; GENETICS; IMMUNOLOGY; NOTE; VIROLOGY;

FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; VACCINES, DNA; VIRAL VACCINES; WEST NILE VIRUS VACCINES;

EID: 39149105632     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/523655     Document Type: Editorial

References (21)

1. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98-109.
2. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007; 44:850-6.
3. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 2002; 33:330-42.
4. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1-11.
5. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81:331-40.
6. Zent O, Broker M. Tick-borne encephalitis vaccines: past and present. Expert Rev Vaccines 2005; 4:747-55.
7. Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005; 19:151-68, ix.
8. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25:1727-34.
9. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-28.
10. Minke JM, Siger L, Karaca K, et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 2004; 18:221-30.
11. Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006; 103:6694-9.
12. Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75:4040-7.
13. Chang GJ, Davis BS, Stringfield C, Lutz C. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection. Vaccine 2007; 25:2325-30.
14. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196:1732-40 (in this issue).
15. Chang GJ, Kuno G, Purdy DE, Davis BS. Recent advancement in flavivirus vaccine development. Expert Rev Vaccines 2004; 3:199-220.
16. Lowe DB, Shearer MH, Kennedy RC. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem 2006; 98:235-42.
17. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59:141-75.
18. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004; 78:8312-21.
19. Centers for Disease Control and Prevention. West Nile virus activity - United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:556-9.
20. Zohrabian A, Hayes EB, Petersen LR. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis 2006; 12:375-80.
21. Jester PM, Tilden SJ, Li Y, Whitley RJ, Sullender WM. Regulatory challenges: lessons from recent West Nile virus trials in the United States. Contemp Clin Trials 2006; 27:254-9.